ALOXI 0.25 MG / 5 ML I.V. 1 VIAL

* Therapeutic indications:

– Chemotherapy-Induced Nausea And Vomiting In Adults

Aloxi is indicated in adults for:

– the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,

– the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

– Chemotherapy-Induced Nausea And Vomiting In Pediatric Patients Aged 1 Month To Less than 17 Years

Aloxi is indicated in paediatric patients 1 month of age and older for:

– the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

– Postoperative Nausea And Vomiting In Adults

ALOXI is indicated for prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated.

As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, ALOXI is recommended even where the incidence of postoperative nausea and/or vomiting is low.

* Pharmacotherapeutic group:

Antiemetics and antinauseants, serotonin (5HT3) antagonists. ATC code: A04AA05

* Mechanism of Action:

Palonosetron is a selective high-affinity receptor antagonist of the 5HT3 receptor.